955 related articles for article (PubMed ID: 24004642)
1. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study.
Mehran R; Baber U; Steg PG; Ariti C; Weisz G; Witzenbichler B; Henry TD; Kini AS; Stuckey T; Cohen DJ; Berger PB; Iakovou I; Dangas G; Waksman R; Antoniucci D; Sartori S; Krucoff MW; Hermiller JB; Shawl F; Gibson CM; Chieffo A; Alu M; Moliterno DJ; Colombo A; Pocock S
Lancet; 2013 Nov; 382(9906):1714-22. PubMed ID: 24004642
[TBL] [Abstract][Full Text] [Related]
2. Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry.
Chandrasekhar J; Baber U; Sartori S; Aquino M; Tomey M; Kruckoff M; Moliterno D; Henry TD; Weisz G; Gibson CM; Iakovou I; Kini A; Faggioni M; Vogel B; Farhan S; Colombo A; Steg PG; Witzenbichler B; Chieffo A; Cohen D; Stuckey T; Ariti C; Pocock S; Dangas G; Mehran R
Int J Cardiol; 2017 Sep; 243():132-139. PubMed ID: 28554669
[TBL] [Abstract][Full Text] [Related]
3. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial.
Collet JP; Silvain J; Barthélémy O; Rangé G; Cayla G; Van Belle E; Cuisset T; Elhadad S; Schiele F; Lhoest N; Ohlmann P; Carrié D; Rousseau H; Aubry P; Monségu J; Sabouret P; O'Connor SA; Abtan J; Kerneis M; Saint-Etienne C; Beygui F; Vicaut E; Montalescot G;
Lancet; 2014 Nov; 384(9954):1577-85. PubMed ID: 25037988
[TBL] [Abstract][Full Text] [Related]
4. Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry.
Faggioni M; Baber U; Sartori S; Giustino G; Cohen DJ; Henry TD; Farhan S; Ariti C; Dangas G; Gibson M; Giacoppo D; Krucoff MW; Aquino M; Chandrasekhar J; Moliterno DJ; Colombo A; Vogel B; Chieffo A; Kini AS; Witzenbichler B; Weisz G; Steg PG; Pocock S; Mehran R
JACC Cardiovasc Interv; 2017 Apr; 10(7):645-654. PubMed ID: 28330641
[TBL] [Abstract][Full Text] [Related]
5. Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention.
Faggioni M; Baber U; Sartori S; Chandrasekhar J; Cohen DJ; Henry TD; Claessen BE; Dangas GD; Gibson CM; Krucoff MW; Vogel B; Moliterno DJ; Sorrentino S; Colombo A; Chieffo A; Kini A; Farhan S; Ariti C; Witzenbichler B; Weisz G; Steg PG; Pocock S; Mehran R
Circ Cardiovasc Interv; 2019 Apr; 12(4):e007133. PubMed ID: 30998384
[TBL] [Abstract][Full Text] [Related]
6. Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents.
Yu J; Baber U; Mastoris I; Dangas G; Sartori S; Steg PG; Cohen DJ; Giustino G; Chandrasekhar J; Ariti C; Witzenbichler B; Henry TD; Kini AS; Krucoff MW; Gibson CM; Chieffo A; Moliterno DJ; Colombo A; Pocock S; Mehran R
JACC Cardiovasc Interv; 2016 Jul; 9(14):1461-9. PubMed ID: 27478113
[TBL] [Abstract][Full Text] [Related]
7. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
Chandrasekhar J; Bansilal S; Baber U; Sartori S; Aquino M; Farhan S; Vogel B; Faggioni M; Giustino G; Ariti C; Colombo A; Chieffo A; Kini A; Saporito R; Michael Gibson C; Witzenbichler B; Cohen D; Moliterno D; Stuckey T; Henry T; Pocock S; Dangas G; Gabriel Steg P; Mehran R
Catheter Cardiovasc Interv; 2017 Jun; 89(7):E217-E225. PubMed ID: 27650638
[TBL] [Abstract][Full Text] [Related]
8. Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry.
Sorrentino S; Sartori S; Baber U; Claessen BE; Giustino G; Chandrasekhar J; Chandiramani R; Cohen DJ; Henry TD; Guedeney P; Ariti C; Dangas G; Gibson CM; Krucoff MW; Moliterno DJ; Colombo A; Vogel B; Chieffo A; Kini AS; Witzenbichler B; Weisz G; Steg PG; Pocock S; Urban P; Mehran R
Circ Cardiovasc Interv; 2020 Apr; 13(4):e008226. PubMed ID: 32216472
[TBL] [Abstract][Full Text] [Related]
9. Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry.
Vogel B; Chandrasekhar J; Baber U; Mastoris I; Sartori S; Aquino M; Krucoff MW; Moliterno DJ; Henry TD; Weisz G; Gibson CM; Iakovou I; Kini AS; Farhan S; Sorrentino S; Faggioni M; Colombo A; Steg PG; Witzenbichler B; Chieffo A; Cohen DJ; Stuckey T; Ariti C; Dangas GD; Pocock S; Mehran R
Thromb Haemost; 2019 Oct; 119(10):1704-1711. PubMed ID: 31365942
[TBL] [Abstract][Full Text] [Related]
10. Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study.
Naidu SS; Krucoff MW; Rutledge DR; Mao VW; Zhao W; Zheng Q; Wilburn O; Sudhir K; Simonton C; Hermiller JB
JACC Cardiovasc Interv; 2012 Jun; 5(6):626-35. PubMed ID: 22721657
[TBL] [Abstract][Full Text] [Related]
11. Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients).
Baber U; Li SX; Pinnelas R; Pocock SJ; Krucoff MW; Ariti C; Gibson CM; Steg PG; Weisz G; Witzenbichler B; Henry TD; Kini AS; Stuckey T; Cohen DJ; Iakovou I; Dangas G; Aquino MB; Sartori S; Chieffo A; Moliterno DJ; Colombo A; Mehran R
Circ Cardiovasc Interv; 2018 Mar; 11(3):e006144. PubMed ID: 29870385
[TBL] [Abstract][Full Text] [Related]
12. Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry).
Sorrentino S; Giustino G; Baber U; Sartori S; Cohen DJ; Henry TD; Farhan S; Sharma M; Ariti C; Dangas G; Gibson M; Faggioni M; Krucoff MW; Aquino M; Chandrasekhar J; Moliterno DJ; Colombo A; Vogel B; Chieffo A; Kini AS; Witzenbichler B; Weisz G; Steg PG; Pocock S; Mehran R
Am J Cardiol; 2018 Nov; 122(10):1638-1646. PubMed ID: 30270177
[TBL] [Abstract][Full Text] [Related]
13. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Feres F; Costa RA; Abizaid A; Leon MB; Marin-Neto JA; Botelho RV; King SB; Negoita M; Liu M; de Paula JE; Mangione JA; Meireles GX; Castello HJ; Nicolela EL; Perin MA; Devito FS; Labrunie A; Salvadori D; Gusmão M; Staico R; Costa JR; de Castro JP; Abizaid AS; Bhatt DL;
JAMA; 2013 Dec; 310(23):2510-22. PubMed ID: 24177257
[TBL] [Abstract][Full Text] [Related]
14. Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry.
Moalem K; Baber U; Chandrasekhar J; Claessen BE; Sartori S; Aquino M; Dangas G; Iakovou I; Colombo A; Kini A; Gibson M; Krucoff M; Chieffo A; Moliterno D; Witzenbichler B; Pocock S; Mehran R
Clin Res Cardiol; 2019 Jun; 108(6):643-650. PubMed ID: 30607496
[TBL] [Abstract][Full Text] [Related]
15. Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry.
Joyce LC; Baber U; Claessen BE; Sartori S; Chandrasekhar J; Cohen DJ; Henry TD; Ariti C; Dangas G; Faggioni M; Aoi S; Gibson CM; Aquino M; Krucoff MW; Vogel B; Moliterno DJ; Sorrentino S; Colombo A; Chieffo A; Kini A; Guedeney P; Witzenbichler B; Weisz G; Steg PG; Pocock S; Mehran R
JACC Cardiovasc Interv; 2019 May; 12(10):983-992. PubMed ID: 31122354
[TBL] [Abstract][Full Text] [Related]
16. Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
Musumeci G; Rossini R; Lettieri C; Capodanno D; Romano M; Rosiello R; Guagliumi G; Valsecchi O; Gavazzi A; Angiolillo DJ
Catheter Cardiovasc Interv; 2012 Sep; 80(3):395-405. PubMed ID: 22109961
[TBL] [Abstract][Full Text] [Related]
17. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
18. Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease.
Simsek C; Onuma Y; Magro M; de Boer S; Battes L; van Domburg RT; Boersma E; Serruys PW;
Catheter Cardiovasc Interv; 2010 Jul; 76(1):41-9. PubMed ID: 20310019
[TBL] [Abstract][Full Text] [Related]
19. Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis.
Palmerini T; Sangiorgi D; Valgimigli M; Biondi-Zoccai G; Feres F; Abizaid A; Costa RA; Hong MK; Kim BK; Jang Y; Kim HS; Park KW; Mariani A; Della Riva D; Genereux P; Leon MB; Bhatt DL; Bendetto U; Rapezzi C; Stone GW
J Am Coll Cardiol; 2015 Mar; 65(11):1092-102. PubMed ID: 25790880
[TBL] [Abstract][Full Text] [Related]
20. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
